Merck & Co. and Bayer on Tuesday won Food and Drug Administration approval for the heart failure drug Verquvo, one of the few medicines Merck has recently brought through late-stage development.

The FDA cleared Verquvo to reduce the risk of cardiovascular death or hospitalization in a subset of chronic patients whose hearts can pump less than 45% of the blood in the left ventricle. Patients who have already been hospitalized or needed outpatient intravenous diuretics would be candidates for treatment.

Read full story here.